Invest in Ventoux Biosciences

Revolutionize treatment for Dupuytren's disease.

Fully reserved

$97,550

reserved by 5 investors
This fundraising round for Ventoux Biosciences has reached its maximum, and is not currently accepting additional reservations.

Highlights

1
Dupuytren's impacts >40m patients in US and Europe and global disease market size est. at USD $4.3B
2
Completed in vivo mouse study, achieved anti-fibrotic effects with lead candidate (VEN-201)
3
Advancing lead candidate (VEN-201) to initial FDA meeting and formulation optimization
4
Currently, no approved pharmacologic treatment options to slow / delay progression of Dupuytren's

Our Team


On a mission to deliver novel, first-line, disease modifying therapies for Dupuytren's disease.
























Downloads

Overview